SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Hana Biosciences (NASDAQ:HNAB), a biopharmaceutical company focused on advancing cancer care, will present additional data from the completed Phase I trial results for Talvesta™ (talotrexin) for Injection in non small cell lung cancer (NSCLC) at the 18th Annual EORTC-NCI-AACR symposium on “Molecular Targets and Cancer Therapeutics,” in Prague, Czech Republic. Abstract #464: “Pharmacokinetics of talotrexin (PT-523), a novel aminopterin analogue, in patients with non-small cell lung cancer” will be presented on Friday, November 10th from 12:00pm – 2:00pm.
